Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection

Abstract

Background

In HCV-infected people who fail to achieve sustained virological response after receiving a direct-acting antiviral regimen, virological failure is almost always accompanied by the presence of resistance-associated substitutions (RASs) in the target protein(s). The aim of this long-term observational study was to evaluate the persistence of NS3/4A and NS5A RASs in participants with genotype (GT) 1 infection who relapsed following treatment with a grazoprevir-containing treatment regimen.

Methods

RASs were evaluated at baseline (that is, pre-dose on day 1 of the original treatment), at the time of virological failure, and up to follow-up week 96. A total of 58 participants were included.

Results

In participants treated with elbasvir/grazoprevir ± ribavirin, observed baseline NS3 RASs included 56F, 80K/L, 122N and 170V/I, and observed treatment-emergent NS3 RASs included 36M, 56F/H, 122G, 132I, 156G/I/L/P/T, 168A/E/G/V/Y and 170T. Observed baseline NS5A RASs included 28M/T/V, 30H/R, 31M/V and 93H/N, and treatment-emergent NS5A RASs included 28A/G/S/T, 30H/R, 31M/V and 93H/N/S. Baseline NS3 and NS5A RASs present at time of failure tended to persist during follow-up, and most were detectable for more than 2 years following virological failure. Treatment-emergent NS5A RASs present at time of failure also tended to persist for more than 2 years following virological failure (93%). By contrast, >80% of treatment-emergent NS3 RASs detected at failure had been supplanted by wild type by week 36.

Conclusions

Treatment-emergent NS5A RASs can persist for extended periods of time. Retreatment strategies should take account of the presence of these RASs.

References

Pawlotsky

J.M.

, Hepatitis

Virus resistance to direct-acting antiviral drugs in interferon-free regimens.

Gastroenterology 2016; 151: 70–86.

Grandal

, Pernas

, Tabernilla

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: impact on current therapeutic strategies.

J Med Virol 2018; 90: 1094–1098.

Smith

, Magri

, Bonsall

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.

Hepatology 2018; doi:10.1002/hep.29837.

Bartlett

S.R.

, Grebely

, Eltahla

A.A.

Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: a systematic review.

Hepatol Commun 2017; 1: 379–390.

Serre

S.B.

, Jensen

S.B.

, Ghanem

Hepatitis C virus genotype 1 to 6 protease inhibitor escape variants: in vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle.

Antimicrob Agents Chemother 2016; 60: 3563–3578.

Wang

, Sun

J.H.

, O'Boyle

D.R.

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

Antimicrob Agents Chemother 2013; 57: 2054–2065.

Howe

A.Y.

, Long

, Nickle

Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C.

Antiviral Res 2015; 113: 71–78.

Gottwein

J.M.

, Pham

L.V.

, Mikkelsen

L.S.

Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants.

Gastroenterology 2018; 154: 1435–1448.

Pham

L.V.

, Ramirez

, Gottwein

J.M.

HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models.

Gastroenterology 2018; pii:S0016-5085(18)30212-9.

10.

Summa

, Ludmerer

S.W.

, McCauley

J.A.

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

Antimicrob Agents Chemother 2012; 56: 4161–4167.

11.

Coburn

C.A.

, Meinke

P.T.

, Chang

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.

ChemMedChem 2013; 8: 1930–1940.

12.

Lahser

F.C.

, Bystol

, Curry

The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons.

Antimicrob Agents Chemother 2016; 60: 2954–2964.

13.

Zeuzem

, Ghalib

, Reddy

K.R.

Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial.

Ann Intern Med 2015; 163: 1–13.

14.

Kwo

, Gane

, Peng

C.Y.

Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection.

Gastroenterology 2017; 152: 164–175.

15.

Forns

, Gordon

S.C.

, Zuckerman

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.

J Hepatol 2015; 63: 564–572.

16.

Rockstroh

J.K.

, Nelson

, Katlama

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Lancet HIV 2015; 2: e319–e327.

17.

Roth

, Nelson

D.R.

, Bruchfeld

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination Phase 3 study.

Lancet 2015; 386: 1537–1545.

18.

Hézode

, Colombo

, Bourliere

Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a Phase III study.

Hepatology 2017; 66: 736–745.

19.

ZEPATIER (elbasvir and grazoprevir) tablets, for oral use. Package insert 2018. Merck and Co., Inc., Kenilworth, NJ, USA.

20.

Zepatier (elbasvir 50 mg/grazoprevir 100 mg) film-coated tablets. Summary of product characteristics. Merck Sharp & Dohme Ltd Hoddesdon, Hertfordshire, UK.

21.

Health Canada. Zepatier. Summary basis of decision. (Updated 2 August 2016. Accessed 27 March 2018.) Available from http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/index-eng.php.

22.

Howe

A.Y.

, Black

, Curry

Virologic resistance analysis from a Phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.

Clin Infect Dis 2014; 59: 1657–1665.

23.

Leitner

, Halapi

, Scarlatti

Analysis of heterogeneous viral populations by direct DNA sequencing.

Biotechniques 1993; 15: 120–127.

24.

Koletzki

, Pattery

, Fevery

, Vanhooren

, Stuyver

L.J.

Amplification and sequencing of the hepatitis C virus NS3/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b.

Methods Mol Biol 2013; 1030: 137–149.

25.

Phenotype Analysis Working Group. HCV drAG phenotype and sequence analysis working group. Annals of the Forum for Collaborative HIV Research 2012; 14: 1–8.

26.

Lontok

, Harrington

, Howe

Hepatitis C virus drug resistance-associated substitutions: state of the art summary.

Hepatology 2015; 62: 1623–1632.

27.

Dore

G.J.

, Altice

, Litwin

A.H.

Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial.

Ann Intern Med 2016; 165: 625–634.

28.

Ahmed

, Abushouk

A.I.

, Menshawy

Meta-analysis of grazoprevir plus elbasvir for treatment of hepatitis C virus genotype 1 infection.

Ann Hepatol 2018; 17: 18–32.

29.

McPhee

, Hernandez

, Zhou

Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre- and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.

Antivir Ther 2018; 23: 53–66.

30.

Krishnan

, Vietri

, Furlan

, Duncan

Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey.

Haemophilia 2015; 21: 64–70.

31.

Dvory-Sobol

, Wyles

, Ouyang

Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir.

J Hepatol 2015; 62 Suppl 2: S221.

32.

AASLD/IDSA HCV Guidance Panel.

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Hepatology 2015; 62: 932–954.

33.

Bourlière M, Gordon SC, Flamm SL, et al.

Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection.

N Engl J Med 2017; 376: 2134–2146.

34.

Wyles

, Wedemeyer

, Ben-Ari

Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.

Hepatology 2017; 66: 1794–1804.